HYBRID EVENT: You can participate in person at London, UK or Virtually from your home or work.

6th Edition of Cardiology World Conference

September 15-17, 2025 | London, UK

September 15 -17, 2025 | London, UK
Cardio 2024

Latest implication of generative AI in cardiology

Dae Wook Lee, Speaker at Heart Conferences
Novartis, Korea, Republic of
Title : Latest implication of generative AI in cardiology

Abstract:

The potential applications of generative AI in the field of cardiology are remarkably broad. Recent research suggests that generative AI is expected to bring a wide range of innovations across the diagnosis and management of cardiovascular diseases. Particularly, the use of generative AI can help reduce the administrative burden on physicians and improve the efficiency of patient care. By automatically summarizing physician-patient dialogues and inputting them into electronic health records, physicians can focus more on direct patient care. Additionally, the use of AI chatbots can automate routine tasks such as scheduling appointments and responding to simple inquiries, reducing the workload for both physicians and staff.

Furthermore, generative AI can accelerate the pace and quality of cardiovascular research. It can rapidly synthesize vast literature and enable integrative analyses, as well as aid in the generation of new hypotheses. This can expedite the development of novel cardiovascular treatments and contribute to improved patient outcomes.

In these ways, generative AI is anticipated to bring about transformative innovations in the field of cardiology, positively impacting both healthcare providers and patients. However, a systematic approach addressing data quality, regulatory compliance, and ethical considerations is necessary to safely and effectively leverage this technology.

Audience Take Away:

  • Provide comprehensive overview on last implication of Generative AI in Cardiology
  • Innovative Medicine with latest Research in Cardiology
  • Sharing of advancement of future new indications for drug discovery using A.I. and digital technology  

Biography:

Dr. Dae Wook Lee is a Medical Director of Novartis Korea in Cardiology, Renal, Metabolism, and Gene Therapy. He was Head of Medical Portfolio Management in Rare disease, Gastroenterology, PDT, Neuroscience and New Molecular entities from the Asia-Pacific Region of Takeda Pharmaceutical Ltd Pte. Dae Wook Lee obtained his Medical Degree from the University of Warwick, U.K. awarded MbChB Medicine & Surgery, and completed MSC Genetic Epidemiology at the Medical Research Unit in the University of Sheffield, U.K with an additional BSc Biomedical Science degree. He also holds an Executive Master of Business Administration (MBA) for Harris College of Business, Faulkner University in North Alabama in U.S. Dae Wook received the Best Research Award in the International Research Awards of Cardiology and Cardiovascular Medicine in 2022.

Watsapp